We provide funding support to ensure promising targets are investigated, and researchers see male contraception as a viable field of scientific enquiry.
Funding Highlight
|
Male Contraceptive Initiative's Fellowship Program
Our Fellowship program provides direct research support to graduates and postdoctoral fellows investigating novel ways of developing or supporting male contraceptives. This program is a critical component of our funding strategy as it helps to ensure promising, talented scientific minds stay engaged in the field, and that they receive the support and mentorship necessary to achieve success. Find additional details below! |
|
On this page we feature information about our funding schemes, links to internal and external announcements, and contact information. Most new research projects are funded through our annual funding cycle that generally opens in early Q2. We also have opportunities for trainee support, including an annual graduate and postdoctoral fellowship program that opens in late Q1. Please see additional details in the below sections.
MCI's Funding Mechanisms
Current MCI Research Funding
Grants & Program-related Investments
MCI's 2023 Grant cycle is now open! MCI plans to fund multiple awards that will allow investigators to take defined, measurable steps forward in male contraceptive research and development. Those interested in applying are encouraged to click the button below to avail application details for the various awards, and please also reach out to us with any questions:
MCI's 2023 Grant cycle is now open! MCI plans to fund multiple awards that will allow investigators to take defined, measurable steps forward in male contraceptive research and development. Those interested in applying are encouraged to click the button below to avail application details for the various awards, and please also reach out to us with any questions:
-------------------------
MCI-BCM Sponsored Target Screening
This opportunity will facilitate the screening of validated male contraceptive targets for small-molecule inhibitors using the DNA-Encoded Chemistry Technology (DEC-Tec) core facilities available in the lab of Dr. Martin Matzuk and Center for Drug Discovery at Baylor College of Medicine (BCM). The purpose of this opportunity is to allow investigators with validated male contraceptive targets to utilize state-of-the-art screening facilities to identify “hit” molecules that bind to the target of interest.
We are now accepting applications for the MCI-BCM Sponsored Target Screening Award. Please see the application announcement for details, and reach out to us with any questions.
This opportunity will facilitate the screening of validated male contraceptive targets for small-molecule inhibitors using the DNA-Encoded Chemistry Technology (DEC-Tec) core facilities available in the lab of Dr. Martin Matzuk and Center for Drug Discovery at Baylor College of Medicine (BCM). The purpose of this opportunity is to allow investigators with validated male contraceptive targets to utilize state-of-the-art screening facilities to identify “hit” molecules that bind to the target of interest.
We are now accepting applications for the MCI-BCM Sponsored Target Screening Award. Please see the application announcement for details, and reach out to us with any questions.
-------------------------
For information about future grant opportunities please reach out to grants@malecontraceptive.org, and be sure to subscribe to our newsletter at the bottom of this page in order to be notified of the latest Male Contraceptive Initiative funding opportunities!
MCI's Trainee & Youth Funding Opportunities
Trainee Fellowships
Male Contraceptive Initiative supports a fellowship program for graduate students and postdoctoral trainees working with senior investigators in the field of male contraceptives. Our 2023 Fellowship cycle is now open and we are accepting applications. Please click the button below for application details or reach out to us at grants@malecontraceptive.org with any questions.
Male Contraceptive Initiative supports a fellowship program for graduate students and postdoctoral trainees working with senior investigators in the field of male contraceptives. Our 2023 Fellowship cycle is now open and we are accepting applications. Please click the button below for application details or reach out to us at grants@malecontraceptive.org with any questions.
-------------------------
Trainee Success Program
MCI supports the career development of graduate and postdoctoral trainees directly through our Success program. Applications are accepted on a rolling basis for any activity or need that advances the career of a trainee interested in the field of male contraception. Examples of eligible activities include travel grants, digital conferences, workshops, and other professional development opportunities. Applications are evaluated based on relevance of the proposed activity, applicant strength and available funds. Applicants are encouraged to contact grants@malecontraceptive.org for questions regarding eligibility.
MCI supports the career development of graduate and postdoctoral trainees directly through our Success program. Applications are accepted on a rolling basis for any activity or need that advances the career of a trainee interested in the field of male contraception. Examples of eligible activities include travel grants, digital conferences, workshops, and other professional development opportunities. Applications are evaluated based on relevance of the proposed activity, applicant strength and available funds. Applicants are encouraged to contact grants@malecontraceptive.org for questions regarding eligibility.
-------------------------
The Beverly Tucker Award
Beverly Tucker, MPH, MPIA, PMP, is a founding board member of Male Contraceptive Initiative and has an illustrious career in global health spanning decades, as well as continents. She is a champion for male contraception, and passionate about supporting scientists all over the world. The annual Tucker Award was established in 2020 to support professional development in the setting of international health. Male Contraceptive Initiative’s Beverly Tucker Award provides up to $5,000 to support a student or professional residing outside of the United States to travel internationally for the purposes of career development. We are currently accepting applications for the Tucker Award. Please see the application details for more information, or reach out to us with any questions at grants@malecontraceptive.org.
Beverly Tucker, MPH, MPIA, PMP, is a founding board member of Male Contraceptive Initiative and has an illustrious career in global health spanning decades, as well as continents. She is a champion for male contraception, and passionate about supporting scientists all over the world. The annual Tucker Award was established in 2020 to support professional development in the setting of international health. Male Contraceptive Initiative’s Beverly Tucker Award provides up to $5,000 to support a student or professional residing outside of the United States to travel internationally for the purposes of career development. We are currently accepting applications for the Tucker Award. Please see the application details for more information, or reach out to us with any questions at grants@malecontraceptive.org.
-------------------------
MCI's Youth Advisory Board Undergraduate Project Grant
MCI's Youth Advisory Board (YAB) is a group of young people (ages 16-28) providing their perspectives to our work and advocating for male contraception. This request for applications is for undergraduate students interested in working on projects related to new male contraception. Applications for the 2022 grant are now closed, but those interested in learning more are encouraged to contact grants@malecontraceptive.org for questions regarding future opportunities.
MCI's Youth Advisory Board (YAB) is a group of young people (ages 16-28) providing their perspectives to our work and advocating for male contraception. This request for applications is for undergraduate students interested in working on projects related to new male contraception. Applications for the 2022 grant are now closed, but those interested in learning more are encouraged to contact grants@malecontraceptive.org for questions regarding future opportunities.
External Funding Opportunities
Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)
This funding opportunity from NICHD provides investigators access to the Chemical Synthesis and Optimization Facility, with capability in preclinical services including Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., protein generation, X-ray crystallography, high throughput screening, structure activity relationships, hit-to-lead generation, drug metabolism). Applications are due May 30, 2023; January 2, 2024; May 2, 2024; January 2, 2025; May 2, 2025.
This funding opportunity from NICHD provides investigators access to the Chemical Synthesis and Optimization Facility, with capability in preclinical services including Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., protein generation, X-ray crystallography, high throughput screening, structure activity relationships, hit-to-lead generation, drug metabolism). Applications are due May 30, 2023; January 2, 2024; May 2, 2024; January 2, 2025; May 2, 2025.
-------------------------
Biological Testing Facility (X01 Clinical Trial Not Allowed)
This funding opportunity is to provide investigators with a mechanism to request services from the NICHD’s Biological Testing Facility would advance their contraceptive development program. This facility has the capabilities and capacity for preclinical services including Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., protein generation, X-ray crystallography, high throughput screening, structure activity relationships, hit-to-lead generation, drug metabolism). Applications are due May 30, 2023; January 2, 2024; May 2, 2024; January 2, 2025; and May 2, 2025.
This funding opportunity is to provide investigators with a mechanism to request services from the NICHD’s Biological Testing Facility would advance their contraceptive development program. This facility has the capabilities and capacity for preclinical services including Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., protein generation, X-ray crystallography, high throughput screening, structure activity relationships, hit-to-lead generation, drug metabolism). Applications are due May 30, 2023; January 2, 2024; May 2, 2024; January 2, 2025; and May 2, 2025.
-------------------------
MATRIX Prevention Challenges: Overcoming Impediments to HIV Prevention RFA
This funding opportunity seeks to support the development of solutions to specific challenges in the field of HIV prevention. Investigators and institutions from Kenya, South Africa, Zimbabwe, United States (US), European Union (EU), or United Kingdom (UK), are invited to apply to this request for applications (RFA) sponsored by the MATRIX project and USAID. Letter of intent and fact-finding questions are due June 1, 2023. Applications are due August 1, 2023.
This funding opportunity seeks to support the development of solutions to specific challenges in the field of HIV prevention. Investigators and institutions from Kenya, South Africa, Zimbabwe, United States (US), European Union (EU), or United Kingdom (UK), are invited to apply to this request for applications (RFA) sponsored by the MATRIX project and USAID. Letter of intent and fact-finding questions are due June 1, 2023. Applications are due August 1, 2023.
-------------------------
Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)
This funding opportunity from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks to support the development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs). This opportunity is open to technologies, biobehavioral and behavioral/social studies, as well as applications involving pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies using drug development, and formulation science supported by animal model testing. Funding Opportunity Number: PAR-22-222. Next application is due December 7, 2023.
This funding opportunity from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks to support the development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs). This opportunity is open to technologies, biobehavioral and behavioral/social studies, as well as applications involving pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies using drug development, and formulation science supported by animal model testing. Funding Opportunity Number: PAR-22-222. Next application is due December 7, 2023.
-------------------------
Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R43/R44 Clinical Trial Not Allowed)
This funding opportunity from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks to support the development of new and innovative long-acting systemic and non-systemic multipurpose prevention technologies (MPT). The FOA includes support for the development and/or acceptability of MPTs in adolescent and young women. Funding Opportunity Number: PAR-21-297. Letters of intent are due 30 days prior to application receipt date. Next application is due December 9, 2023.
This funding opportunity from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks to support the development of new and innovative long-acting systemic and non-systemic multipurpose prevention technologies (MPT). The FOA includes support for the development and/or acceptability of MPTs in adolescent and young women. Funding Opportunity Number: PAR-21-297. Letters of intent are due 30 days prior to application receipt date. Next application is due December 9, 2023.
-------------------------
Comprehensive Resources for HIV Microbicides and Biomedical Prevention (CRMP)
This contract seeks to provide support services for HIV prevention drug developers including academic (investigators), for-profit and not-for-profit small and large companies, and other product innovators (henceforth identified as Sponsors) for the development of HIV non-vaccine biomedical prevention (nBP) strategies and products. The types of nBPs supported include, but are not limited to, topical microbicides, pre-exposure prophylaxis (PrEP) and Multipurpose Prevention Technologies (MPT’s) for the purpose of preventing HIV transmission and acquisition in adolescents, women, men and transgender individuals. Sponsors seeking these services receive no funding from NIAID, but instead receive products or information generated by NIAID-funded contractors on their behalf. Data and reports are provided in a format that supports a regulatory filing. Applications are reviewed on a rolling basis.
This contract seeks to provide support services for HIV prevention drug developers including academic (investigators), for-profit and not-for-profit small and large companies, and other product innovators (henceforth identified as Sponsors) for the development of HIV non-vaccine biomedical prevention (nBP) strategies and products. The types of nBPs supported include, but are not limited to, topical microbicides, pre-exposure prophylaxis (PrEP) and Multipurpose Prevention Technologies (MPT’s) for the purpose of preventing HIV transmission and acquisition in adolescents, women, men and transgender individuals. Sponsors seeking these services receive no funding from NIAID, but instead receive products or information generated by NIAID-funded contractors on their behalf. Data and reports are provided in a format that supports a regulatory filing. Applications are reviewed on a rolling basis.
